drugset / Trial / NCT02356289

Single Ascending Dose Study of MYK-461 in Healthy Volunteers

NCT02356289

Phase 1 Completed 48 enrolled MyoKardia, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a randomized, double-blind, placebo-controlled, sequential group, single ascending (oral) dose study in healthy volunteers aged 18-55 years.

Timeline

Start
2015-01
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule Oral

Indications

No indication recorded.